Table 2 The impact of educational workshop on healthcare providers’ understanding of pharmacovigilance and the ADRs reporting system (n = 85)
Questions | The correct answer | Frequency and percentage of participants answered correctly | ||
|---|---|---|---|---|
Pre-workshop | Post-workshop | P-valuea | ||
Definition of ADRs | ADR is a response to a drug which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modifications of physiological function | 78 (91.8) | 80 (94.1) | 0.530 |
Definition of pharmacovigilance | Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem | 74 (87.1) | 85 (100.0) | 0.001* |
Definition of ADR type A | A reaction that is predictable from the known pharmacology of a drug and are associated with high morbidity and low mortality | 46 (54.1) | 74 (87.1) | < 0.001* |
Definition of ADR type B | A reaction that is idiosyncratic, and cannot be predicted from the known pharmacology of a drug and are associated with low morbidity and high mortality | 41 (48.2) | 65 (76.5) | < 0.001* |
ADR should be reported only when serious and unexpected | No | 61 (71.8) | 67 (78.8) | 0.320 |
Always report adverse effects related to herbal medications | Yes | 70 (82.4) | 75 (88.2) | 0.227 |
ADR should not be reported until the specific medication that caused it is known | No | 37 (43.5) | 48 (56.5) | 0.101 |
Location of the national pharmacovigilance center in Jordan | Yes | 48 (56.5) | 76 (89.4) | < 0.001* |
Overall knowledge score (mean ± SD) | 5.6 ± 1.9 | 6.6 ± 1.1 | < 0.001b* | |